Study of Retifanlimab and Ruxolitinib for Certain Cancers
Treatments studied
Part of Cancer, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced kidney cancer (clear cell) or lung cancer (non-small cell) that has grown despite prior treatment with a PD-1/PD-L1 immunotherapy drug.
- You have declined or exhausted standard treatment options for your cancer.
- You are able to take oral medications and follow the study schedule.
- You have not been treated before with a Janus kinase (JAK) inhibitor drug (like ruxolitinib).
- You have not had more than one prior line of PD-1/PD-L1 therapy, and your best response to that therapy was stable disease, partial shrinkage, or complete disappearance of the cancer (not progression).
- You do not have uncontrolled infections, active autoimmune disease requiring steroids, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs together—vorolanib (a pill that targets blood vessels in tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer)—for people with advanced kidney cancer whose prior immunotherapy combination stopped working.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
This Phase 1 trial tests a new combination of two drugs—L19IL2 (an immune-boosting protein) and ruxolitinib (a JAK inhibitor that reduces inflammation)—in patients with advanced pancreatic, colorectal, or kidney cancer that has stopped responding to other treatments. The goal is to see if this combination is safe and can help shrink tumors.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus either lenvatinib or axitinib for people with advanced clear cell kidney cancer that continued to grow after the first treatment. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.